Sunil Shah, CEO, o2h Ventures, has won the prestigious UKBAA Angel Investor of the Year Award for his active participation in backing high growth potential startups and early-stage businesses in the UK. Sunil’s contribution has been instrumental in the growth of biotech in UK. He has been investing into the biotech therapeutics sector since many years – a sector from which traditionally many angel investors have stayed away. Over the years, Sunil has championed Seed Enterprise Investment (EIS) Angel investing and biotech therapeutics to generate investment into companies.
The UK Business Angels Association (UKBAA) is the national trade association representing angel and early stage investment. o2h Ventures Limited has launched the o2h Therapeutics and Artificial Intelligence fund which is the first Seed Enterprise Investment Scheme fund in the UK solely focused on early stage biotech therapeutics and related AI opportunities.
Speaking about his win,Sunil Shah said, “I feel both privileged and delighted to win this award. I plan to use this award to champion Angel and Early stage investment into biotech companies.
“I believe this is an area in which Great Britain has world’s leading expertise, on par with the massive biotech base in Boston/San Francisco, however, comparatively, there is little appetite to invest in our early stage biotech companies. Large Pharma have publicly stated that they will seek to bring in large amount of innovation from outside (through research collaborations, option deals, and acquisitions) and so I believe this positively changes the investment rationale for Angels and early stage investors into biotech companies.
“In the UK, we also have a secret weapon of tax efficient investing through the Enterprise Investment Scheme.”
